Cancer
shifts constantly.

ADJUVANT

RECURRENCE

ADVANCED

PROGRESSION

Completely transform the way you see what's next, now.

Guardant Complete is a portfolio of revolutionary liquid and tissue precision oncology tests, all with the convenience of a single testing company.1,2

Exceptional customer service every step of the way.

Circle of icons representing the comprehensive customer support provided by Guardant Health, including medical affairs, field team, cutting-edge products, Guardant Access, digital ordering, client services, and mobile phlebotomy.

Giving your patients the answers they need.

Guardant Complete takes a closer look at your patient’s cancer to answer the important questions about their treatment plan.

*Patient timeline is for illustrative purposes only.

†Confirmation of medical necessity is required if Guardant360 TissueNext is ordered with another Guardant Health profiling test.

‡Liquid and tissue testing may be initiated at the same time, but sample processing does not occur concurrently.

ctDNA, circulating tumor DNA.

References: 1. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023. 2. Guardant360 TissueNext™ Assay Specifications. Guardant Health, Inc. Redwood City, CA. 3. Backgrounder: Guardant Reveal™ liquid biopsy test. Guardant Health, Inc. Redwood City, CA. 4. FDA News Release. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test. August 7, 2020. Accessed July 27, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test 5. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047 6. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 7. Guardant360® Assay Specifications. Guardant Health, Inc. Redwood City, CA. 8. Page RD, Drusbosky LM, Dada H, et al. Clinical outcomes for plasma-based comprehensive genomic profiling versus standard-of-care tissue testing in advanced non–small cell lung cancer. Clin Lung Cancer. 2022;23(1):72-81. doi:10.1016/j.cllc.2021.10.001